Drugs Made In America Acquisition Corp. (DMAA)
Drugs Made In America Acquisition will go public soon, but the exact IPO date is still unknown.
IPO Price
$10.00
Shares Offered
20,000,000
Deal Size
$200.00M
Company Description
Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
We intend to focus our search for business combination targets in the pharmaceutical industry.
Drugs Made In America Acquisition Corp.
| Country | United States |
| Founded | 2024 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Lynn Stockwell |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, FL 33301 United States | |
| Phone | (954) 870-3099 |
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002028614 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Lee Seng Chi | Chief Executive Officer, Director, and Chairman of the Board of Directors |
| See Sian Seong | Chief Financial Officer |
| Thien Chiet Chai | Non-executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 6, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 1, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |